Kane Biotech Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
KNE
- Investments
-
3
- Share Price
-
$0.02
- (As of Friday Closing)
Kane Biotech General Information
Description
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Contact Information
Website
ir.kanebiotech.comCorporate Office
- 263-196 Innovation Drive
- Suite 190
- Winnipeg, Manitoba R3T 6C5
- Canada
Corporate Office
- 263-196 Innovation Drive
- Suite 190
- Winnipeg, Manitoba R3T 6C5
- Canada
Kane Biotech Timeline
Kane Biotech Stock Performance
As of 13-Nov-2026, Kane Biotech’s stock price is $0.02. Its current market cap is $4.31M with 205M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.01 - $0.03 | $4.31M | 205M | 69K | -$0.01 |
Kane Biotech Financials Summary
As of 30-Jun-2026, Kane Biotech has a trailing 12-month revenue of $43.3K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,400 | 5,879 | 11,751 | 15,337 |
| Revenue | 43 | 306 | 1,517 | 110 |
| EBITDA | (1,831) | (1,747) | (2,707) | (2,306) |
| Net Income | (1,955) | (1,946) | 4,447 | (3,728) |
| Total Assets | 1,568 | 1,996 | 1,738 | 4,282 |
| Total Debt | 1,381 | 1,682 | 1,516 | 6,974 |
Kane Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kane Biotech Comparisons
Industry
Financing
Details
Kane Biotech Competitors (6)
One of Kane Biotech’s 6 competitors is Armata Pharmaceuticals, a Formerly VC-backed company based in Los Angeles, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Armata Pharmaceuticals | Formerly VC-backed | Los Angeles, CA | ||||
| Xellia Pharmaceuticals | Private Equity-Backed | Copenhagen, Denmark | ||||
| VBI Vaccines | Corporation | Cambridge, MA | ||||
| EyeD Pharma | Venture Capital-Backed | Seraing, Belgium | ||||
| Innovotech (Edmonton) | Formerly VC-backed | Edmonton, Canada |
Kane Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kane Biotech Patents
Kane Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025156055-A1 | System for dispensing spray gels for treatment of wounds and infections and methods of use thereof | Pending | 25-Jan-2024 | ||
| EP-4753735-A1 | Composition, methods, and uses thereof for acne prevention, reduction, and treatment | Pending | 28-Jul-2023 | ||
| WO-2025024918-A1 | Composition, methods, and uses thereof for acne prevention, reduction, and treatment | Inactive | 28-Jul-2023 | ||
| CA-3169163-A1 | Coactive combinations of antimicrobials with dispersinb | Pending | 02-Mar-2020 | ||
| EP-4114444-A1 | Coactive combinations of antimicrobials with dispersinb | Inactive | 02-Mar-2020 | C12N9/2402 |
Kane Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kane Biotech Investments & Acquisitions (3)
Kane Biotech’s most recent deal was a Merger/Acquisition with FB Dermatology. The deal was made on 12-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| FB Dermatology | 12-Nov-2024 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| STEM Animal Health | 28-Sep-2020 | Joint Venture | Other Consumer Non-Durables | ||
| Vinson Biotech | 24-Sep-2003 | Merger/Acquisition | Biotechnology |
Kane Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Kane Biotech Exits (1)
Kane Biotech’s most recent exit was on 28-Sep-2020 from STEM Animal Health. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| STEM Animal Health | 28-Sep-2020 | Completed |
|
Kane Biotech FAQs
-
When was Kane Biotech founded?
Kane Biotech was founded in 2001.
-
Where is Kane Biotech headquartered?
Kane Biotech is headquartered in Winnipeg, Canada.
-
What is the size of Kane Biotech?
Kane Biotech has 25 total employees.
-
What industry is Kane Biotech in?
Kane Biotech’s primary industry is Pharmaceuticals.
-
Is Kane Biotech a private or public company?
Kane Biotech is a Public company.
-
What is Kane Biotech’s stock symbol?
The ticker symbol for Kane Biotech is KNE.
-
What is the current stock price of Kane Biotech?
As of 13-Nov-2026 the stock price of Kane Biotech is $0.02.
-
What is the current market cap of Kane Biotech?
The current market capitalization of Kane Biotech is $4.31M.
-
What is Kane Biotech’s current revenue?
The trailing twelve month revenue for Kane Biotech is $43.3K.
-
Who are Kane Biotech’s competitors?
Armata Pharmaceuticals, Xellia Pharmaceuticals, VBI Vaccines, EyeD Pharma, and Innovotech (Edmonton) are some of the 6 competitors of Kane Biotech.
-
What is Kane Biotech’s annual earnings per share (EPS)?
Kane Biotech’s EPS for 12 months was -$0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
